Evelo Biosciences to Host KOL Discussion on Treatment Advances for All Stages of Psoriasis and Potential of SINTAX Medicines
March 07, 2022 06:00 ET
|
Evelo Biosciences, Inc.
CAMBRIDGE, Mass., March 07, 2022 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq:EVLO), a clinical stage biotechnology company developing SINTAX™ medicines as a new modality of orally delivered...
Evelo Biosciences to Participate in Cowen 42nd Annual Health Care Conference
March 02, 2022 07:00 ET
|
Evelo Biosciences, Inc.
CAMBRIDGE, Mass., March 02, 2022 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq:EVLO), a clinical stage biotechnology company developing SINTAX™ medicines as a new modality of orally delivered...
Durable and Deepening Clinical Responses Observed in Post-Treatment Period of Evelo Bioscience’s Phase 2 Clinical Trial of Oral EDP1815 in Psoriasis
February 28, 2022 06:00 ET
|
Evelo Biosciences, Inc.
-18/30 patients maintained a PASI-50 or greater response at 24 weeks post-treatment--9/20 patients experienced a deepening of response from PASI-50 to at least PASI-75 during post-treatment period--No...
Evelo Biosciences Announces Dosing of First Patient in Phase 2 Trial of EDP1815 in Atopic Dermatitis
February 17, 2022 07:00 ET
|
Evelo Biosciences, Inc.
CAMBRIDGE, Mass., Feb. 17, 2022 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq:EVLO), a clinical stage biotechnology company developing SINTAX™ medicines as a new modality of orally delivered...
Evelo Biosciences Announces Highly Significant Reductions in Clinically Validated Inflammatory Cytokines in EDP1815 Phase 2 Psoriasis Trial
February 07, 2022 07:00 ET
|
Evelo Biosciences, Inc.
Treatment with EDP1815 led to reduced production of cytokines IL-6, IL-8, and TNF in blood cellsCytokine analysis supports gut-restricted action of EDP1815 to resolve inflammation throughout the...
Evelo Biosciences Presents Data on EDP1815 Mechanism of Action and Supporting Ongoing Clinical Development for Inflammatory Diseases
January 17, 2022 07:00 ET
|
Evelo Biosciences, Inc.
CAMBRIDGE, Mass., Jan. 17, 2022 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq:EVLO), a clinical stage biotechnology company developing SINTAX™ medicines as a new modality of orally delivered...
Evelo Biosciences Announces Key 2022 Strategic Priorities and Upcoming Catalysts
January 04, 2022 07:00 ET
|
Evelo Biosciences, Inc.
CAMBRIDGE, Mass., Jan. 04, 2022 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq:EVLO), a clinical stage biotechnology company developing SINTAX™ medicines as a new modality of orally delivered...
Evelo Biosciences Added to Nasdaq Biotechnology Index
December 14, 2021 07:00 ET
|
Evelo Biosciences, Inc.
CAMBRIDGE, Mass., Dec. 14, 2021 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq:EVLO), a clinical stage biotechnology company developing SINTAX™ medicines as a new modality of orally delivered...
Evelo Biosciences to Present at 2021 Jefferies London Healthcare Conference
November 09, 2021 07:00 ET
|
Evelo Biosciences, Inc.
CAMBRIDGE, Mass., Nov. 09, 2021 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq:EVLO), a clinical stage biotechnology company developing SINTAX™ medicines as a new modality of orally delivered...
Evelo Biosciences Reports Third Quarter 2021 Financial Results and Business Highlights
October 28, 2021 07:00 ET
|
Evelo Biosciences, Inc.
–Positive Phase 2 clinical data with EDP1815 in psoriasis; moving towards registration studies––Dosing for Phase 2 EDP1815 Phase 2 trial in atopic dermatitis to begin during 4Q 2021––Preclinical data...